Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Thymosin alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide also known as thymalfasin; branded approvals reported outside North America do not validate an unspecified material. A 2025 multicentre double-blind phase 3 trial in 1,106 adults with sepsis found no clear reduction in 28-day all-cause mortality. Older, smaller studies in other diseases are not interchangeable.

Aliases reviewed
Thymalfasin, Ta1, Zadaxin
Sources checked
2026-09-15
Editorial status
published

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. It is studied as an immune-modulating peptide across infection, critical illness, cancer adjunct, and immune-function settings.

Identity

Thymosin alpha-1 is a 28-amino-acid peptide also known as thymalfasin; branded approvals reported outside North America do not validate an unspecified material.

Biological mechanism or research interest

It is studied as an immune-modulating peptide across infection, critical illness, cancer adjunct, and immune-function settings.

Verified approved human uses

No Canadian or U.S. approved use was verified in the reviewed sources. This does not claim worldwide absence.

Investigational human evidence

A 2025 multicentre double-blind phase 3 trial in 1,106 adults with sepsis found no clear reduction in 28-day all-cause mortality. Older, smaller studies in other diseases are not interchangeable.

Immune boosting, infection treatment, cancer benefit, and broad resilience claims exceed the mixed, disease-specific evidence.

Human versus animal or cell evidence

Immune-marker mechanisms do not prove patient-important outcomes, as the large sepsis trial illustrates.

Limitations and known risks

FDA identifies inadequate safety information for proposed compounded use, including potential immunogenicity and peptide-characterization complexity.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.